Actively Recruiting

Age: 18Years - 75Years
All Genders
NCT07530770

Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis

Led by Qianfoshan Hospital · Updated on 2026-04-21

20

Participants Needed

2

Research Sites

65 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

An open-label study will evaluate effects of Benralizumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis

CONDITIONS

Official Title

Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female patients aged 18 to 75 years
  • Physician diagnosis of Allergic Bronchopulmonary Aspergillosis meeting ISHAM criteria
  • Predisposing bronchial asthma
  • Positive Aspergillus skin test or elevated specific IgE to Aspergillus fumigatus, niger, or flavus
  • Elevated total IgE levels (>1,000 IU/mL) or acceptable lower levels with other criteria
  • At least two of three: precipitating IgG antibodies to Aspergillus, radiographic lung opacities, or eosinophil count >500 cells/uL in steroid-naive patients
  • Severe chronic asthma for at least 12 months requiring high-dose inhaled corticosteroids plus an asthma controller
  • Current treatment with high daily doses of inhaled corticosteroids (>500ug fluticasone propionate equivalent) plus another asthma controller for at least 3 months
  • History of at least 2 asthma exacerbations requiring systemic corticosteroids in the past 12 months
  • Weight over 40 kg
Not Eligible

You will not qualify if you...

  • Significant lung diseases other than asthma with ABPA (e.g., COPD, cystic fibrosis, sarcoid, pulmonary fibrosis)
  • History of anaphylaxis to any biologic therapy
  • Known allergy or hypersensitivity to benralizumab or its components
  • Current smokers or former smokers with over 10 pack-years smoking history
  • Pregnant, breastfeeding, or lactating women
  • Participation in another interventional or post-authorization safety study unless observational

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China

Jinan, Shandong, China, 250014

Actively Recruiting

2

Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University

Jinan, Shandong, China, 250014

Actively Recruiting

Loading map...

Research Team

Q

Qian Qi, Dr.

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here